Immunoengineering

(I-329) Modeling the Immune Processes of Atherosclerosis in a Tissue Engineered Blood Vessel

(H-310) Mesenchymal stromal cells and alpha-1 antitrypsin have a strong synergy in modulating inflammation and its resolution

(H-299) Engineered RIG-I Activating Nanoparticles for Glioblastoma Immunotherapy

(H-298) Antigen-loaded extracellular vesicles to regulate adaptive immune responses and drive immunological tolerance

(H-303) Efferocytosis of Viable, but not heat-inactivated allogeneic human MSCs converts human monocytes to an immunosuppressive phenotype

(H-300) Engineering trophoblast extracellular vesicle-delivering hydrogels for localized tolerance induction in a cell transplant site

(H-301) Nanobubble Ultrasound Contrast Agents as Delivery Vehicles for Tolerogenic Peptides in Mouse Models of Type 1 Diabetes

(H-304) Biomimetic Glycopolymer Nanoparticles for Modulating Protein Corona and Immune Interactions for Cancer Drug Delivery

(H-307) RAPID RECRUITMENT OF MONOCYTES DICTATES THE EFFICACY OF IMAGE-GUIDED RADIOTHERAPY

(H-308) A Fully Synthetic Ex-vivo Germinal Center Model Elucidates Differential Responses of B cells to Antigen Presentation Method

(H-305) Synthesis of Programable Hydrogel at Room Temperature with Tuneable Release for Various Delivery Applications

(H-306) Electrospun Fiber Surface Roughness Modulates Macrophage Polarization for Soft-Tissue Injury Regeneration

(H-312) Delivery of IL-4 mRNA via lipid nanoparticles for the intracellular control of macrophage phenotype

(H-311) In situ formation of long-lasting tumor-specific T memory stem cells using nanoVax

(H-309) Evaluation of Decellularized Porcine Dermal Hydrogel for Biointegration of Acellular Dermal Matrix in an Irradiated Murine Model

(I-333) Characterization of decellularized porcine brain-derived hydrogels for intratumoral administration of cellular immunotherapies in post-resection glioblastoma

(I-334) Mathematical Analysis of Differential Model for Melanoma Immunotherapy

(I-331) Self-assembly peptide neoantigen for personalized cancer vaccines

(I-332) Development of Macromolecular Polymeric STING Agonists for Cancer Immunotherapy Applications

(I-330) Immunomodulatory Strategies to Improve Burn Wound Healing

(I-327) Immunomodulatory polymer-based nanoparticles for controlling and treating obesity

(I-328) Depletion of Tuberculosis-Associated Myeloid-Derived Suppressor Cells with Synthetic Nanoparticle Antibodies (SNAbs)

(I-324) Microfluidics-mediated isolation of tumor-reactive cells from peripheral blood for next-generation cancer immunotherapy

(I-325) Bioengineered Colon-Specific Immune Niche for the Treatment of Ulcerative Colitis

(I-326) The role of neuroinflammation at the early stage of experimental glaucoma

(H-318) FLT3L-Mediated Modulation of Macrophage Behavior and Wound Healing: Towards Advanced Immunomodulatory Strategies

(H-319) Immunomodulation of T cells and NK cells by ECM derived biomaterials in murine volumetric muscle loss

(H-320) The Role of Macrophage Scavenger Receptors in Engineered Biomaterial Scaffold Remodeling

(I-321) Chemoenzymatic Synthesis of Immune-Regulating Mucin Mimics

(I-322) Using ELISA to Identify Autoantigenic Peptides for Expansion of Pathogenic CD4s

(I-323) Localized Delivery of Cytokine mRNA to Enhance Anti-Tumor Immunity and to Minimize Systemic Toxicity

(H-317) Optical Imaging of Immune-Targeted Rare Earth Nanoparticles for Prognostication of Metastasis in a Syngeneic Model of Breast Cancer

(H-315) Immune Modulation for the Treatment of Type 1 Diabetes

(H-316) In vitro characterization of macrophage phenotype in a spheroid tumor model of melanoma

(H-313) Licensed hMSCs exhibit immunomodulatory capacity enhanced in macrophage co-culture

(H-314) Macrophage Vaccine as a Potent Initiator of Activation of NK, CD4+, and CD8+ T Cells for Robust Tumor Control

(J-364) Single-Cell Analysis of the T Cell Response in Murine Foreign Body Response

(J-366) Shifting the balance of inflammatory and pro-resolving lipid mediators in volumetric muscle loss (VML) injury

(J-367) Utilizing lymphatic-based vaccination for antitumoral immunity

(J-368) Autofluorescence lifetime imaging resolves metabolic abnormalities in T cells from SLE patients

(J-369) Optimization and scale-up production of oral inulin gel for modulation of the gut microbiome for cancer immunotherapy

(J-371) Modifying Immune Responses Using Trained Immunity

(J-372) Remote Scaffold Implants Identify Biomarkers of Transplant Rejection by Graft Recipient Sex

(J-373) Cancer Therapeutic Efficacy of Immune Booster Peptides

(J-375) Comparing PEGylated and Glycosylated Polyplexes for mRNA Delivery

(J-376) CD2 Regulates Cellular Cytotoxicity Mediated By Natural Killer Cells

(J-377) Phagocytosis and Polarization

(J-378) Redirecting Type I Interferon Signal Flow Through Mesoscale Clustering and De Novo Activation

(J-379) Therapeutic macrophage-checkpoint silencing using siRNA-lipid nanoparticles in metastatic ovarian cancer

(J-380) Immunomodulation for tissue repair through affinity-based binding partners

(J-381) The Fate of Monocytes Under Various Inflammatory Conditions

(J-382) Effects of storage time and temperature on mesenchymal stromal cell extracellular vesicle yield and modulation of microglia morphology

(J-383) Lymphatic endothelial cell (LEC)-targeting nanocarriers for modulating vaccine-induced immunity

(J-384) Developing 4th Generation CAR T Cell microRNA Biofactories for Solid Tumor Treatment

(J-385) Developing a Label-Free, Non-Invasive Potency-on-a-chip Assay for CAR T Therapy

(J-386) Efficacy of Sublingually Delivered IL-1β3 and TNF Dual Cytokine Immunotherapy

(J-387) Modulating Immune Responses to RNA Vaccines Using Small-Drug Activated Self-Replicating RNA Gene Circuits

(J-388) Antigen Presentation and Adaptive Immune Response to Muscle Injury and Biomaterial Implantation

(J-389) Degradable Microcarrier Scaffolds (DMSs) for Scalable CAR T Cell Manufacturing

(J-390) Predicting and Modeling Resistance to Organ Allograft Tolerance using a Minimally-Invasive Implant

(J-391) Investigate Short-Term Mechanosensing Response in T Cell Subsets

(J-392) Development of PLG antisense oligonucleotide conjugated nanoparticles to reduce inflammation

(J-393) Investigating RASA2 Overexpression to Reduce CAR T Cell On-Target Off-Tumor Toxicity

(J-394) In Living Color: Isosulfan Blue As a Tool to Study Immuno-Engineering In Vivo